title: Regulatory Factors Influencing Usage of Retinal Pharmaceuticals: A Look Both Home and Abroad.
authors.affiliation: Retina Consultants of Houston, Houston, Texas.
authors.forename: Daniel E
authors.initials: DE
authors.lastname: Croft
authors.affiliation: Retina Consultants of Houston, Houston, Texas; Blanton Eye Institute, Houston Methodist Hospital, Houston, Texas. Electronic address: ccwmd@houstonretina.com.
authors.forename: Charles C
authors.initials: CC
authors.lastname: Wykoff
authors.affiliation: Department of Ophthalmology, City Hospital Triemli, Zurich, Switzerland.
authors.forename: Stephan
authors.initials: S
authors.lastname: Michels
authors.affiliation: Center for Experimental Medicine, The Queen's University of Belfast, Belfast, United Kingdom.
authors.forename: Usha
authors.initials: U
authors.lastname: Chakravarthy
authors.affiliation: Department of Ophthalmology and Visual Sciences, Dalhousie University, Halifax, Canada.
authors.forename: Alan F
authors.initials: AF
authors.lastname: Cruess
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D017326:Clinical Trials, Phase III as Topic; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D004335:Drug and Narcotic Control / Q000331:legislation & jurisprudence*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000517:prevention & control; D005062:European Union; D006801:Humans; D007880:Legislation, Drug / Q000458:organization & administration* / Q000592:standards; D008268:Macular Degeneration / Q000188:drug therapy*; D004364:Pharmaceutical Preparations / Q000008:administration & dosage*; D012170:Retinal Vein Occlusion / Q000188:drug therapy*; D014481:United States; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D004364:Pharmaceutical Preparations; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A